Sterling Capital Management’s Viking Therapeutics VKTX Stock Holding History

Sterling Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$276K	Buy	7,069 +2,065	+41%	+$66.7K	﹤0.01%	1115
2026 Q1	$163K	Sell	5,004 -995	-17%	-$32K	﹤0.01%	1255
2025 Q4	$211K	Sell	5,999 -219	-4%	-$7.76K	﹤0.01%	1302
2025 Q3	$163K	Sell	6,218 -836	-12%	-$24.9K	﹤0.01%	1381
2025 Q2	$187K	Buy	7,054 +3,989	+130%	+$105K	﹤0.01%	1265
2025 Q1	$74K	Sell	3,065 -2,008	-40%	-$63.5K	﹤0.01%	1346
2024 Q4	$204K	Sell	5,073 -35,290	-87%	-$2.01M	﹤0.01%	1267
2024 Q3	$2.56M	Buy	+40,363	New	+$2.37M	0.03%	326

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Sterling Capital Management's VKTX Position: Q2 2026 in Review

Sterling Capital Management increased its Viking Therapeutics (VKTX) stake by 41% in Q2 2026, buying an estimated $66.7K and bringing the position to 7,069 shares worth $276K. The position accounts for ﹤0.01% of the portfolio, ranked #1115.

Sterling Capital Management first reported a position in VKTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.56M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Sterling Capital Management held 7,069 shares of Viking Therapeutics worth $276K as of Q2 2026.
Sterling Capital Management bought 2,065 Viking Therapeutics shares in Q2 2026, an estimated $66.7K.
Viking Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1115 holding.
Sterling Capital Management first reported a position in Viking Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Viking Therapeutics position peaked at $2.56M in Q3 2024.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.